GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » ROC (Joel Greenblatt) %

iCo Therapeutics (iCo Therapeutics) ROC (Joel Greenblatt) % : -123,200.00% (As of Mar. 2021)


View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. iCo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was -123,200.00%.

The historical rank and industry rank for iCo Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ICOTF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -87671.43   Med: -42112.12   Max: -24740
Current: -28708.33

During the past 13 years, iCo Therapeutics's highest ROC (Joel Greenblatt) % was -24740.00%. The lowest was -87671.43%. And the median was -42112.12%.

ICOTF's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -334.375 vs ICOTF: -28708.33

iCo Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 1.00% per year.


iCo Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for iCo Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics ROC (Joel Greenblatt) % Chart

iCo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41,466.67 -57,700.00 -63,150.00 -42,114.29 -33,257.14

iCo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33,818.18 -13,236.36 -14,800.00 -20,160.00 -123,200.00

Competitive Comparison of iCo Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, iCo Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iCo Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's ROC (Joel Greenblatt) % falls into.



iCo Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.022) - (1.013 + 0 + 0)
=-0.991

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.019) - (1.528 + 0 + 0)
=-1.509

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of iCo Therapeutics for the quarter that ended in Mar. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2020  Q: Mar. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.464/( ( (0.002 + max(-0.991, 0)) + (0.002 + max(-1.509, 0)) )/ 2 )
=-2.464/( ( 0.002 + 0.002 )/ 2 )
=-2.464/0.002
=-123,200.00 %

Note: The EBIT data used here is four times the quarterly (Mar. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iCo Therapeutics  (GREY:ICOTF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


iCo Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


iCo Therapeutics (iCo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines